1 |
Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 35:548-552, 2005
DOI
ScienceOn
|
2 |
Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 54:414-419, 2002
DOI
ScienceOn
|
3 |
Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 60:321-328, 2007
DOI
ScienceOn
|
4 |
Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangio carcinomas by surgical resection and radiotherapy. Am J Surg 159:91-97; discussion 97-98, 1990
DOI
ScienceOn
|
5 |
Lai EC, Chu KM, Lo CY, Fan ST, Lo CM, Wong J. Choice of palliation for malignant hilar biliary obstruction. Am J Surg 163:208-212, 1992
DOI
ScienceOn
|
6 |
Park J, Kim MH, Kim KP, Park do H, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3:298-305, 2009
DOI
ScienceOn
|
7 |
Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224:463-473; discussion 473-475, 1996
DOI
ScienceOn
|
8 |
Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features. Am J Med 38:241-256, 1965
DOI
ScienceOn
|
9 |
Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 15:4240-4262, 2009
DOI
ScienceOn
|
10 |
Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 344:1655-1660, 1994
DOI
ScienceOn
|
11 |
Gruenberger B, Schueller J, Tamandl D, Kaczirek K, Schernthaner G, Gruenberger T. K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study. J Clin Oncol 27(Suppl 15):4586, 2009 [Abstract]
|
12 |
Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mossner J. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 31:291-298, 2000
DOI
ScienceOn
|
13 |
Cheon YK, Cho YD, Baek SH, Cha SW, Moon JH, Kim YS, Lee JS, Lee MS, Shim CS, Kim BS. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol 44:280-287, 2004
|
14 |
Ortner ME, Caca K, Berr F, LiebetruthJ, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mossner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125:1355-1363, 2003
DOI
ScienceOn
|
15 |
Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C, Mössner J, Hauss J, Witzigmann H. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 97:2783-2790, 2003
DOI
ScienceOn
|
16 |
Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramontuc O, uvete F. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GER OR study. Ann Oncol 15:1339-1343, 2004
DOI
ScienceOn
|
17 |
Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896-902, 2007
DOI
ScienceOn
|
18 |
Ohnishi H, Asada M, Shichijo Y, Iijima N, Itobayashi E, Shimura K, Suzuki T, Yoshida S, Mine T. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology 42:265-268, 1995
|
19 |
Ishii H, Furuse J, Nagase M, Kawashima M, Ikeda H, Yoshino M. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology 51:954-957, 2004
|
20 |
Golfieri R, Giampalma E, Renzulli M, Galuppi A,Vicenzi L, Galaverni MC, Cappelli A. Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo 20:757-760, 2006
|
21 |
Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, Miyamoto N. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 57:1357-1365, 2003
DOI
ScienceOn
|
22 |
Kuvshinoff BW, Armstrong JG, Fong Y, Schupak K, Getradjman G, Heffernan N, Blumgart LH. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 82:1522-1525, 1995
DOI
ScienceOn
|
23 |
Zhu AX, Meyerhardt JA, Balszkowsky LS, Muzikansky A, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Sahani DV. Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) and oxaliplatin (OX). J Clin Oncol 27(Suppl 15):4578, 2009 [Abstract]
DOI
|
24 |
Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14:2311-2315, 1996
DOI
|
25 |
Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9:653-656, 1998
DOI
ScienceOn
|
26 |
Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 87:702-704, 2002
DOI
ScienceOn
|
27 |
Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783-789, 2001
|
28 |
Lee GW, Kang JH, Kim HG, Lee JS, Lee JS, Jang JS. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 29:127-131, 2006
DOI
ScienceOn
|
29 |
Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332-2338, 2005
DOI
ScienceOn
|
30 |
Serafini FM, Sachs D, Bloomston M, Carey LC, Karl RC, Murr MM, Rosemurgy AS. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 67:839-843; discussion 843-844, 2001
|
31 |
Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73:148-153, 2009
DOI
ScienceOn
|
32 |
Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, Donehower RC, Laheru DA, Hruban RH, Abrams RA. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 68:178-182, 2007
DOI
ScienceOn
|
33 |
Figueras J, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, Rafecas A, Torras J, Jaurrieta E. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl 6:786-794, 2000
DOI
|
34 |
Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH. Effects of 5- fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23:425-428, 2000
DOI
ScienceOn
|
35 |
Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 13:1470-1479, 2009
DOI
ScienceOn
|
36 |
Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 27:173-179, 2003
|
37 |
Stein DE, Heron DE, Rosato EL, Anne PR, Topham AK. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy . Am J Clin Oncol 28:21-23, 2005
DOI
ScienceOn
|
38 |
Itoh H, Nishijima K, Kurosaka Y, Takegawa S, Kiriyama M, Dohba S, Kojima Y, Saitoh Y. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci 50:2231-2242, 2005
DOI
ScienceOn
|
39 |
Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46:581-587, 2000
DOI
ScienceOn
|
40 |
Kaiser GM, Sotiropoulos GC, Jauch KW, Lohe F, Hirner A, Kalff JC, Konigsrainer A, Steurer W, Senninger N, Brockmann JG, Schlitt HJ, Zulke C, Buchler MW, Schemmer P, Settmacher U, Hauss J, Lippert H, Hopt UT, Otto G, Heiss MM, Bechstein WO, Timm S, Klar E, Holscher AH, Rogiers X, Stangl M, Hohenberger W, Muller V, Molmenti EP, Fouzas I, Erhard J, Malago M, Paul A, Broelsch CE, Lang H. Liver transplantation for hilar cholangiocarcinoma: a German survey. Transplant Proc 40:3191-3193, 2008
DOI
ScienceOn
|
41 |
Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242:451-458, 2005
|
42 |
Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 47:644-649, 2000
|
43 |
Thongprasert S. Therole of chemotherapy in cholangiocarcinoma. Ann Oncol 16(Suppl 2):ii93-ii96, 2005
|
44 |
Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?: a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685-1695, 2002
DOI
ScienceOn
|
45 |
Forsmo HM, Horn A, Viste A, Hoem D, Ovrebo K. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 7:412-417, 2008
|
46 |
Todoroki T, Kawamoto T, Koike N, Takahashi H, Yoshida S, Kashiwagi H, Takada Y, Otsuka M, Fukao K. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 87:306-313, 2000
DOI
ScienceOn
|
47 |
Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B, Larson D, Nagorney DM. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 139:514-523, 2004
DOI
ScienceOn
|
48 |
Song GW, Lee SG, Lee YJ, Park KM, Hwang S, Kim KH, Ahn CS, Moon DB, Ha TY, Ryu JH, Park JI, Lee HJ. Analysis of survival predictors after surgical resection of hilar cholangiocarcinoma (HCCC) in a single institute with large volume. Korean J Hepatobiliary Pancreat Surg 11:32-39, 2007
|
49 |
Jang JY. Clinical outcome of surgical treatment for Klatskin tumor. Korean J Pancreas Biliary Tract 14:130-134, 2009
|
50 |
Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patiens. Transplantation 69:1633-1637, 2000
|
51 |
Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 47: 354-362, 1998
DOI
ScienceOn
|
52 |
Deviere J, Baize M, de Toeuf J, Cremer M. Long-term follow-up of patients with hilar malignant Stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 34:95-101, 1988
DOI
ScienceOn
|
53 |
Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 230:663-671, 1999
DOI
ScienceOn
|
54 |
Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, Katoh H. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospeilar cstudy. Ann Surg 240:95-101, 2004
DOI
ScienceOn
|
55 |
Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 238:720-727, 2003
DOI
ScienceOn
|
56 |
Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, Carey LC, Rosemurgy AS. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 190:810-815, 2005
DOI
ScienceOn
|
57 |
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507-517, 2001
DOI
ScienceOn
|
58 |
Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 9:43-57, 2004
|